Synlett 2013; 24(6): 697-700
DOI: 10.1055/s-0032-1318253
letter
© Georg Thieme Verlag Stuttgart · New York

An Efficient and Straightforward Method to New Organic Compounds: Homodrimane Sesquiterpenoids with Diazine Units

Kaleria Kuchkova
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Aculina Aricu
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Alic Barba
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Pavel Vlad
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Sergiu Shova
b   ‘P. Poni’ Institute of Macromolecular Chemistry, Aleea Grigore Ghica Voda 41-A, Iasi 700487, Romania
,
Elena Secara
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Nicon Ungur
a   Institute of Chemistry of the Academy of Sciences of Moldova, Academy 3, Chisinau, 2028, Republic of Moldova
,
Gheorghită Zbancioc
c   ‘Al. I. Cuza’ University of Iasi, Organic and Biochemistry Department, Bd. Carol 11, Iasi 700506, Romania   Fax: +40(232)201313   Email: ionelm@uaic.ro
,
Ionel I. Mangalagiu*
c   ‘Al. I. Cuza’ University of Iasi, Organic and Biochemistry Department, Bd. Carol 11, Iasi 700506, Romania   Fax: +40(232)201313   Email: ionelm@uaic.ro
› Author Affiliations
Further Information

Publication History

Received: 07 January 2013

Accepted: 28 January 2013

Publication Date:
13 February 2013 (online)


Abstract

A comprehensive study of the synthesis and structure of new homodrimane sesquiterpenoids with diazine skeleton is presented. This is the first synthesis of homodrimane sesquiterpenoids with diazine skeleton. In the same time, an efficient way for the one-pot bisacylation of 2-aminopyrimidine is reported. The structure of the bisacylamide was proven unambiguously, including the single-crystal X-ray structure determination. A reliable explication and feasible reaction mechanisms for the obtained compounds are presented.

 
  • References and Notes

  • 1 Zhan ZJ, Ying YM, Ma LF, Shan WG. Nat. Prod. Rep. 2011; 28: 594
  • 2 Jansen BJ. M, de Groot A. Nat. Prod. Rep. 2004; 21: 449
  • 3 Choudhary MI, Musharraf SG, Sami A Atta-ur-Rahman Helv. Chim. Acta 2004; 87: 2685
  • 4 Allouche N, Apel C, Martin MT, Dumontet V, Guéritte F, Litaudon M. Phytochemistry 2009; 70: 546
  • 5 Zhou H, Zhu T, Cai S, Gu Q, Li D. Chem. Pharm. Bull. 2011; 59: 762
  • 6 Ying BP, Peiser GD, Ji Y.-Y, Mathias KM, Karasina F, Hwang YS. J. Agric. Food Chem. 1995; 43: 826
  • 7 Nelson Z, Georges L, Guy S. Pest Manage Sci. 2010; 66: 1324
  • 8 Achelle S, Plé N. Curr. Org. Synth. 2012; 9: 163
  • 9 Achelle S, Barsella A, Baudequin C, Bertrand C, Françoise RG. J. Org. Chem. 2012; 77: 4087
  • 10 Mangalagiu II. Curr. Org. Chem. 2011; 15: 730
  • 11 Zbancioc AM, Zbancioc G, Tanase C, Miron A, Ursu C, Mangalagiu II. Lett. Drug Des. Discovery 2010; 7: 644
  • 12 Martins MA. P, Frizzo CP, Moreira DN, Buriol L, Machado P. Chem. Rev. 2009; 109: 4140
  • 13 Butnariu R, Mangalagiu II. Bioorg. Med. Chem. 2009; 17: 2823
  • 14 Balan AM, Florea O, Moldoveanu C, Zbancioc G, Iurea D, Mangalagiu II. Eur. J. Med. Chem. 2009; 2275
  • 15 Yves LJ. Bioorg. Med. Chem. 2007; 15: 2479
  • 16 Moldoveanu C, Mangalagiu II. Helv. Chim. Acta 2005; 88: 2747
  • 17 De Clercq E. J. Med. Chem. 2005; 48: 1297
  • 18 Culf AS, Melanson JA, Ouellette RJ, Briand GG. Tetrahedron Lett. 2012; 53: 3301
  • 19 Katritzky AR, Suzuki K, Singh SK. ARKIVOC 2004; (i): 12
  • 20 Morizzo E, Capelli F, Lenzi O, Catarzi D, Varano F, Filacchioni G, Vincenzi F, Varani K, Andrea Borea P, Colotta V, Moro S. J. Med. Chem. 2007; 50: 6596
  • 21 Kuchkova KI, Arîcu AN, Barba AN, Vlad PF, Lipkovskii J, Simonov YuS, Kravtov VK. Chem. Nat. Comp. 2011; 47: 223
  • 22 Kuchkova KI, Aricu AN, Vlad PF, Deleanu C, Nicolescu A. Chem. Nat. Comp. 2010; 46: 539
  • 23 Kuchkova KI, Aricu AN, Vlad PF. Chem. Nat. Comp. 2009; 45: 367
  • 24 Martres P, Perfetiti P, Zahra J.-P, Waegell B, Giraudi E, Petrzilka M. Tetrahedron Lett. 1993; 34: 629
  • 25 Vlad PF, Dragalina GA, Coltsa MN. Russ. J. Gen. Chem. 1977; 47: 943
  • 26 Vlad PF, Ungur ND, Aricu AN, Andreeva IY. Russ. Chem. Bull. 1997; 46: 800
  • 27 Martres P, Perfetiti P, Zahra J.-P, Waegell B. Tetrahedron Lett. 1993; 34: 3127
  • 28 The crystal structure for compound 8 has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 893824. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(1223)336033 or email: deposit@ccdc.cam.ac.uk].
  • 29 Typical Procedure for the Synthesis of Bicyclohomofarnezenic Acid Derivatives with Diazine Skeleton – Method I To a solution of the acid 4 (200 mg, 0.80 mmol) in anhydrous benzene (4 mL) a solution of (COCl)2 (0.8 mL, 1.16 g, 9.17 mmol) in anhydrous benzene (2 mL) was added. Then the reaction mixture was stirred at r.t. for 1 h and then refluxed (1 h). Benzene and excess (COCl)2 were evaporated under reduced pressure. To the residue CH2Cl2 (8 mL) and aminodiazine 6ac (1.26 mmol) were added, and the resulting mixture was heated (40 °C) under stirring for an appropriate period of time [2 h for 4-aminopyrimidine (6a), 5 h for aminopyrazine (6b), 15 h for 2-aminopyrimidine (6c)]. A precipitate was filtered off, washed with CH2Cl2, and the filtrate was concentrated to dryness. The residue was dissolved in CHCl3 (3 mL) and was purified by flash chromatography on silica (CHCl3). The following supplementary operations and remarks were to be pointed out in the case of reaction products derived from amine 6c: elution with CHCl3 afforded gradually the bisacylamide 8, the monoacyl amide 7c, and a two-component mixture. This mixture was subject to a second flash over silica (PE–Et2O, 8:2) when monoacyl amide 7c and some unreacted acid 4 were separated.
  • 30 Typical Procedure for the Synthesis of Bicyclohomofarnezenic Acid Derivatives with Diazine Skeleton – Method II A solution of DCC (215 mg, 1.04 mmol), DMAP (100 mg, 0.82 mmol), aminodiazine 6ac (0.84 mmol), and the acid 4 (100 mg, 0.40 mmol) in CH2Cl2 (4 mL) was stirred at r.t. for an appropriate period of time [10 h for 4-aminopyrimidine (6a), 28 h for aminopyrazine (6b), 5 h for 2-aminopyrimidine (6c)]. A precipitate was filtered off, washed with CH2Cl2, and the filtrate was evaporated under reduced pressure. The residue was dissolved in CHCl3 (5 mL) and was purified by flash chromatography on silica (CHCl3). The following supplementary operations and remarks were to be pointed out in the case of reaction products derived from amine 6c: elution with CHCl3 gave a mixture of the bisacylamide 8 and the urea 9. For the separation of these compounds, the mixture was extracted first with PE. The undissolved precipitate was filtered off and washed thoroughly with PE when the bisacylamide 8 was obtained. The filtrate solution was evaporated to dryness and the residue crystallized from MeCN giving urea 9. The remaining silica from the first flash chromatography was washed with CHCl3 affording a mixture of the monoacyl amide 7c and dicyclohexylurea 10. This mixture was extracted with Et2O. The undissolved precipitate of dicyclohexylurea 10 was filtered off, and the ether filtrate was concentrated to dryness. The obtained residue was crystallized from MeCN to give the monoacyl amide 7c.
  • 31 Δ8,13-Bicyclohomofarnezenic Acid Amide (7c) White crystals; mp 149–150 °C. [α]D 26 –14.8 (c 0.6, CHCl3). IR: 3262, 3189, 3111 (NH amide), 3078, 892 (semicyclic methylene), 1725 (C=O, amide), 1649, 1574, 1435, 1155 (pyrimidine cycle) cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.60 (2 H, d, J = 8.0 Hz, H-18, H-20), 8.51 (1 H, br s, NH), 6.99 (1 H, t, J = 4.9 Hz, H-19), 4.79 (1 H, s, Ha-13), 4.54 (1 H, s, Hb-13), 2.95 (1 H, dd, J = 16.6, 10.1 Hz, Ha-11), 2.79 (1 H, dd, J = 16.6, 3.7 Hz, Hb-11), 2.56 (1 H, dd, J = 10.1, 3.7 Hz, H-9), 2.41 (1 H, ddd, J = 13.0, 4.0, 2.4 Hz, Ha-7), 2.15 (1 H, td, J = 13.0, 4.0 Hz, Hb-7), 1.26 (1 H, dd, J = 12.6, 2.1 Hz, H-5), 1.80–1.10 (8 H, m), 0.90 (3 H, s, H-14), 0.83 (3 H, s, H-15), 0.76 (3 H, s, H-16). 13C NMR (100 MHz, CDCl3): δ = 172.64 (s, C-12), 158.32 (d, C-20), 158.32 (d, C-18), 157.70 (s, C-17), 149.27 (s, C-8), 116.14 (d, C-19), 106.51 (t, C-13), 55.21 (d, C-5), 52.27 (d, C-9), 42.12 (t, C-3), 39.24 (s, C-10), 39.09 (t, C-1), 37.67 (t, C-7), 33.57 (q, C-14), 33.56 (t, C-11), 33.53 (s, C-4), 24.13 (t, C-6), 21.77 (q, C-15), 19.35 (t, C-2), 14.75 (q, C-16).
  • 32 2-Bis-Δ8,13-bicyclohomofarnezenoylaminopyrimidine (8) White crystals; mp 205–206 °C. [α]D 26 27.78 (c 0.33, CHCl3). IR: 3088, 897 (semicyclic methylene), 1704 (C=O, amide), 1644, 1567, 1460, 1410, 1162 (pyrimidine cycle) cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.87 (2 H, d, J = 4.9 Hz, H-18, H-20), 7.34 (1 H, t, J = 4.9 Hz, H-19), 4.80 (2 H, s, Ha-13, Ha-13′), 4.52 (2 H, s, Hb-13, Hb-13′), 2.72 (2 H, dd, J = 16.9, 2.6 Hz, Ha-11, Ha-11′), 2.56 (2 H, dd, 16.9, 10.2 Hz, Hb-11, Hb-11′), 2.49 (2 H, dd, J = 10.0, 2.0 Hz, H-9, H-9′), 2.39 (2 H, ddd, J = 13.0, 4.0, 2.3 Hz, Ha-7, Ha-7′), 2.10 (2 H, td, J = 13.0, 5.0, Hz, Hb-7, Hb-7′), 1.18 (2 H, dd, J = 12.5, 2.5 Hz, H-5, H-5′), 1.80–1.03 (16 H, m), 0.87 (6 H, s, H-14, H-14′), 0.79 (6 H, s, H-15, H-15′), 0.59 (6 H, s, H-16, H-16′). 13C NMR (100 MHz,CDCl3): δ = 175.22 (s, C-12), 159.95 (s, C-17), 159.34 (d, C-18), 159.34 (d, C-20), 148.92 (s, C-8), 120.20 (d, C-19), 106.41 (t, C-13), 55.12 (d, C-5), 51.90 (d, C-9), 42.05 (t, C-3), 39.03 (t, C-1), 38.90 (s, C-10), 37.54 (t, C-7), 34.38 (t, C-11), 33.56 (q, C-14), 33.49 (s, C-4), 23.97 (t, C-6), 21.73 (q, C-15), 19.25 (t, C-2), 14.63 (q, C-16).
  • 33 N8,13-Bicyclohomofarnezenoyl-N,N′-Dicyclohexylurea (10) White crystals; mp 166–167 °C. [α]D 26 11.9 (c 1.34, CHCl3). IR: 3266 (NH amide), 3074, 879 (semicyclic methylene), 1698 (C=O amide), 1658 (C=O amide) cm–1. 1H NMR (400 MHz, CDCl3): δ = 6.47 (1 H, br s, NH), 4.75 (1 H, s, Ha-13), 4.43 (1 H, s, Hb-13), 4.02 (1 H, m, H-17), 3.72 (1 H, m, H-24), 2.49 (3 H, m, Ha-11, Hb-11, H-9), 2.38 (1 H, ddd, J = 12.9, 3.8, 2.2 Hz, Ha-7), 2.13 (1 H, td, J = 12.9, 4.9 Hz, Hb-7), 2.05–1.05 (28 H, m), 1.22 (1 H, dd, J = 12.7, 2.1 Hz, H-5), 0.90 (3 H, s, H-14), 0.82 (3 H, s, H-15), 0.71 (3 H, s, H-16). 13C NMR (100 MHz, CDCl3): δ = 172.51 (s, C-12), 154.32 (s, C-23), 149.45 (s, C-8), 105.97 (t, C-13), 55.15 (d, C-5), 52.09 (d, C-9), 49.86 (d, C-17), 49.13(d, C-24), 42.04 (t, C-3), 39.09 (t, C-1), 39.02 (s, C-10), 37.68 (t, C-7), 33.56 (q, C-14), 33.50 (s, C-4), 32.80 (t, C-25 and C-29), 31.55 (t, C-11), 31.22 (t, C-22), 30.69 (t, C-18), 26.25 (t, C-19 and C-21), 25.48 (t, C-27), 25.40 (t, C-20), 24.73 (t, C-26 and C-28), 24.05 (t, C-6), 21.73 (q, C-15), 19.29 (t, C-2), 14.81 (q, C-16).